Updated Global Biological Drugs Industry & Market Analysis by Visiongain Published at MarketPublishers.com

05 Apr 2012 • by Natalie Aster

LONDON – Where is the market for biological drugs heading? How will twenty leading biologics – including Avastin, Enbrel, Humira and Herceptin – perform from 2012? What does the future hold? What about the leading companies including Roche, Amgen, Novo Nordisk, Abbott and many others? How will biosimilars (follow-on protein products) affect the market? All these questions and other key issues are answered and addressed in the research study.

Updated research study “World Biological Drugs Market 2012-2022” worked out by Visiongain provides a true and unbiased insight into the global biological drugs market development over the next decade. In particular, the study features:

  • potential revenues to 2022 for the world market and submarkets; 
  • revenue forecasts to 2022 for 20 leading products; 
  • market forecasting to 2022 for US, Japan, EU5, China and India; 
  • leading pharmaceutical companies along with their activities, as well as market and industry prospects; 
  • SWOT & STEP analyses and discussion of R&D activities, with a look at pipeline trends; 
  • competition and opportunities influencing sales; 
  • drivers and restraints of the industry and market; 
  • three detailed research interviews.

Report Details:

World Biological Drugs Market 2012-2022
Published: February, 2012
Pages: 242
Price: US$ 2.642,00

More updated and new research studies by the publisher can be found at Visiongain page.

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com